{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:02Z","timestamp":1793672942379,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xphs.2024.09.020","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T18:46:48Z","timestamp":1727549208000},"page":"289-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The importance of surface composition and wettability on the dissolution performance of high drug loading amorphous dispersion formulations"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-7806","authenticated-orcid":false,"given":"Tze Ning","family":"Hiew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-1884","authenticated-orcid":false,"given":"Marina A.","family":"Solomos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-2897","authenticated-orcid":false,"given":"Prapti","family":"Kafle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7630-7063","authenticated-orcid":false,"given":"Hector","family":"Polyzois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-9195","authenticated-orcid":false,"given":"Dmitry Y.","family":"Zemlyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8613-5111","authenticated-orcid":false,"given":"Ashish","family":"Punia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7531-1888","authenticated-orcid":false,"given":"Luke","family":"Schenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-6021","authenticated-orcid":false,"given":"Lynne S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.xphs.2024.09.020_bib0001","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.xphs.2019.04.006","article-title":"Effect of amorphous nanoparticle size on bioavailability of anacetrapib in dogs","volume":"108","author":"Kesisoglou","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.020_bib0002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","article-title":"Physical chemistry of supersaturated solutions and implications for oral absorption","volume":"101","author":"Taylor","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2024.09.020_bib0003","article-title":"Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023","volume":"7","author":"Moseson","year":"2024","journal-title":"Int J Pharm X"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.020_bib0004","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijpharm.2017.10.051","article-title":"Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery \u2013 an update","volume":"535","author":"Jermain","year":"2018","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.020_bib0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1208\/s12249-020-01854-2","article-title":"Innovations in thermal processing: hot-melt extrusion and KinetiSol\u00ae dispersing","volume":"21","author":"Tan","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2024.09.020_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3852126","article-title":"Elbasvir\/grazoprevir: a review of the latest agent in the fight against hepatitis C","volume":"2016","author":"Bell","year":"2016","journal-title":"Int J Hepatol"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.020_bib0007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0008","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.xphs.2024.09.020_bib0009","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.xphs.2024.09.020_bib0010","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.020_bib0011","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/A:1016292416526","article-title":"Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures","volume":"12","author":"Hancock","year":"1995","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0928-0987(00)00173-1","article-title":"Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25","volume":"12","author":"Van den Mooter","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.020_bib0013","article-title":"Delaying the first nucleation event of amorphous solid dispersions above the polymer overlap concentration (c*): PVP and PVPVA in posaconazole","author":"Song","year":"2024","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.020_bib0014","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1021\/acs.molpharmaceut.0c00061","article-title":"Polymer type impacts amorphous solubility and drug-rich phase colloidal stability: a mechanistic study using nuclear magnetic resonance spectroscopy","volume":"17","author":"Ueda","year":"2020","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1021\/acs.molpharmaceut.0c01174","article-title":"Effect of polymer species on maximum aqueous phase supersaturation revealed by quantitative nuclear magnetic resonance spectroscopy","volume":"18","author":"Ueda","year":"2021","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.020_bib0016","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11095-009-0021-1","article-title":"Understanding the behavior of amorphous pharmaceutical systems during dissolution","volume":"27","author":"Alonzo","year":"2010","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.020_bib0017","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/jps.22579","article-title":"Dissolution and precipitation behavior of amorphous solid dispersions","volume":"100","author":"Alonzo","year":"2011","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.020_bib0018","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.xphs.2022.03.020","article-title":"Formulation and processing strategies which underpin susceptibility to matrix crystallization in amorphous solid dispersions","volume":"112","author":"Moseson","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.020_bib0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2022.09.056","article-title":"Combining drug salt formation with amorphous solid dispersions \u2013 a double edged sword","volume":"352","author":"Hiew","year":"2022","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/acs.molpharmaceut.1c00481","article-title":"Balancing solid-state stability and dissolution performance of lumefantrine amorphous solid dispersions: the role of polymer choice and drug\u2013polymer interactions","volume":"19","author":"Hiew","year":"2022","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0021","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/acs.molpharmaceut.8b01261","article-title":"Insights into the dissolution mechanism of ritonavir\u2013copovidone amorphous solid dispersions: importance of congruent release for enhanced performance","volume":"16","author":"Indulkar","year":"2019","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.020_bib0022","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acs.molpharmaceut.2c00892","article-title":"Dissolution mechanisms of amorphous solid dispersions: role of drug load and molecular interactions","volume":"20","author":"Deac","year":"2023","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.020_bib0023","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1021\/acs.molpharmaceut.3c00020","article-title":"Dissolution mechanisms of amorphous solid dispersions: a close look at the dissolution interface","volume":"20","author":"Deac","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.09.020_bib0024","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.3c00586","article-title":"Does media choice matter when evaluating the performance of hydroxypropyl methylcellulose acetate succinate-based amorphous solid dispersions?","author":"Bapat","year":"2023","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0025","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1021\/acs.molpharmaceut.3c01106","article-title":"Interplay of drug\u2013polymer interactions and release performance for HPMCAS-based amorphous solid dispersions","volume":"21","author":"Bapat","year":"2024","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.020_bib0026","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1021\/acs.molpharmaceut.3c00174","article-title":"Fed- and fasted-state performance of pretomanid amorphous solid dispersions formulated with an enteric polymer","volume":"20","author":"Nguyen","year":"2023","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.020_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071034","article-title":"Hierarchical particle approach for co-precipitated amorphous solid dispersions for use in preclinical in vivo studies","volume":"13","author":"Schenck","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.xphs.2024.09.020_bib0028","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s11095-022-03308-9","article-title":"Assessing the interrelationship of microstructure, properties, drug release performance, and preparation process for amorphous solid dispersions via noninvasive imaging analytics and material characterization","volume":"39","author":"Jia","year":"2022","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.020_bib0029","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.xphs.2022.12.019","article-title":"Improving dissolution performance and drug loading of amorphous dispersions through a hierarchical particle approach","volume":"112","author":"Hiew","year":"2023","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0030","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.xphs.2018.09.008","article-title":"Impact of method of preparation of amorphous solid dispersions on mechanical properties: Comparison of coprecipitation and spray drying","volume":"108","author":"Hou","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.09.020_bib0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijpharm.2019.01.009","article-title":"Building a better particle: leveraging physicochemical understanding of amorphous solid dispersions and a hierarchical particle approach for improved delivery at high drug loadings","volume":"559","author":"Schenck","year":"2019","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.020_bib0032","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.xphs.2022.09.007","article-title":"High bulk-density amorphous dispersions to enable direct compression of reduced tablet size amorphous dosage units","volume":"112","author":"Frank","year":"2023","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0033","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/ac60111a017","article-title":"Colorimetric method for determination of sugars and related substances","volume":"28","author":"DuBois","year":"1956","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.020_bib0034","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/acs.oprd.1c00380","article-title":"Coprecipitated amorphous dispersions as drug substance: opportunities and challenges","volume":"26","author":"Strotman","year":"2022","journal-title":"Org Process Res Dev"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.020_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9797(90)90315-F","article-title":"Relationships between adsorption and wetting of surfactant solutions","volume":"140","author":"Gau","year":"1990","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.xphs.2024.09.020_bib0036","unstructured":"Petermann O, Sprehe M. Process for producing a cellulose ether acetate succinate. WO 2016\/069338 A1, May 6, 2016."},{"issue":"12","key":"10.1016\/j.xphs.2024.09.020_bib0037","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s11095-006-9104-4","article-title":"A review of poloxamer 407 pharmaceutical and pharmacological characteristics","volume":"23","author":"Dumortier","year":"2006","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.020_bib0038","doi-asserted-by":"crossref","first-page":"e00390","DOI":"10.1016\/j.heliyon.2017.e00390","article-title":"Thermogelling properties of purified poloxamer 407","volume":"3","author":"Fakhari","year":"2017","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0039","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2004.09.028","article-title":"Sustained release of lidocaine from Poloxamer 407 gels","volume":"288","author":"Ricci","year":"2005","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/ma9909455","article-title":"Gelation kinetics of gelatin:\u2009 a master curve and network modeling","volume":"33","author":"Normand","year":"2000","journal-title":"Macromolecules"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.020_bib0041","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1211\/0022357001774787","article-title":"Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion","volume":"52","author":"Ross","year":"2000","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0042","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/jbm.b.31366","article-title":"Novel drug-loaded gelatin films and their sustained-release performance","volume":"90B","author":"Lin","year":"2009","journal-title":"J Biomed Mater Res"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.020_bib0043","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2007.03.003","article-title":"Recombinant gelatin hydrogels for the sustained release of proteins","volume":"119","author":"Sutter","year":"2007","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2024.09.020_bib0044","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejpb.2014.11.026","article-title":"Modified thermoresponsive Poloxamer 407 and chitosan sol\u2013gels as potential sustained-release vaccine delivery systems","volume":"89","author":"Kojarunchitt","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2024.09.020_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122120","article-title":"Role of surfactants in improving release from higher drug loading amorphous solid dispersions","volume":"625","author":"Correa-Soto","year":"2022","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.020_bib0046","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-021-03159-w","article-title":"Impact of surfactants on the performance of clopidogrel-copovidone amorphous solid dispersions: increased drug loading and stabilization of nanodroplets","volume":"39","author":"Correa Soto","year":"2022","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.020_bib0047","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jps.24487","article-title":"Hydrodynamic effects on drug dissolution and deaggregation in the small intestine\u2014a study with felodipine as a model drug","volume":"104","author":"Lindfors","year":"2015","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0048","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics10020053","article-title":"Polymer\u2013surfactant system based amorphous solid dispersion: Precipitation inhibition and bioavailability enhancement of itraconazole","volume":"10","author":"Feng","year":"2018","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0049","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/mp5006245","article-title":"Impact of surfactants on the crystallization of aqueous suspensions of celecoxib amorphous solid dispersion spray dried particles","volume":"12","author":"Chen","year":"2015","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.020_bib0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11095-022-03183-4","article-title":"Role of surfactants on release performance of amorphous solid dispersions of ritonavir and copovidone","volume":"39","author":"Indulkar","year":"2022","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T20:35:48Z","timestamp":1734726948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022354924004283"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.020","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of surface composition and wettability on the dissolution performance of high drug loading amorphous dispersion formulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}